The Escherichia coli glucuronylsynthase promoted synthesis of steroid glucuronides: improved practicality and broader scope
作者:Paul Ma、Nicholas Kanizaj、Shu-Ann Chan、David L. Ollis、Malcolm D. McLeod
DOI:10.1039/c4ob00984c
日期:——
Steroid glucuronides can be quickly and conveniently prepared on the milligram scale using theE. coliglucuronylsynthase enzyme followed by purification with solid-phase extraction.
Experimental and Kinetic Studies of the <i>Escherichia coli</i> Glucuronylsynthase: An Engineered Enzyme for the Synthesis of Glucuronide Conjugates
作者:Shane M. Wilkinson、Morgan A. Watson、Anthony C. Willis、Malcolm D. McLeod
DOI:10.1021/jo101914s
日期:2011.4.1
and study of glucuronide metabolites is essential in many fields including pharmaceutical development, sports drug testing, and the detection of agricultural residues. Therefore, the development of improved methods for the synthesis of glucuronide conjugates is an important aim. The glycosynthase derivedfrom E. coli β-glucuronidase provides an efficient, scalable, single-step synthesis of β-glucuronides
[EN] 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME<br/>[FR] ANALOGUES DE L'ACIDE 2-BÊTA-NAPHTHYL-ACÉTIQUE COMME INHIBITEURS D'AKR1C3 ET PROCÉDÉS LES UTILISANT
申请人:UNIV PENNSYLVANIA
公开号:WO2017070448A1
公开(公告)日:2017-04-27
The invention includes 2-β-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are R-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.
Drug metabolites generated by UDP glycosyltransferases (UGTs) are needed for drug development and toxicity studies, especially in the context of safety testing of metabolites during drug development. Because chemical metabolite synthesis can be arduous, various biological approaches have been developed; however, no whole-cell biotransformation with recombinant microbes that express human UGTs was yet achieved. In this study we expressed human UDP glucose-6-dehydrogenase together with several human or rat UGT isoforms in the fission yeast Schizosaccharomyces pombe and generated strains that catalyze the whole-cell glucuronidation of standard substrates. Moreover, we established two methods to obtain stable isotope-labeled glucuronide metabolites: the first uses a labeled aglycon, whereas the second uses 13C6-glucose as a metabolic precursor of isotope-labeled UDP-glucuronic acid and yields a 6-fold labeled glucuronide. The system described here should lead to a significant facilitation in the production of both labeled and unlabeled drug glucuronides for industry and academia.
The invention discloses novel endocrine treatment phytochemicals which affect androgenic status. The method for treatment of 5-alpha-reductase responsive diseases using four novel 5-alpha-reductase inhibitor compounds; leucoanthocyanidin, glabrene, glabridin, and alpha-terpineol is disclosed. Glabridin does not interfere with normal testosterone to androgen receptor binding.